Phase 2 Cardiomyopathy Trial, Recruiting NCT07606274 Sponsor: Nuevocor Pte. Ltd. Condition: Cardiomyopathy
Back to Cardiomyopathy

Phase 2 Cardiomyopathy Trial, Recruiting

NCT07606274
Recruiting Phase 2

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 18 years of age or older and are able to give their own consent to participate
  • People who have been clinically diagnosed with a type of heart muscle disease called dilated cardiomyopathy (DCM) caused by a change in the LMNA gene, where the left side of the heart is not pumping properly
  • People whose LMNA gene mutation has been confirmed as harmful or likely harmful by an approved, accredited genetic testing laboratory
  • People whose heart failure symptoms fall into a mild-to-moderate range (classified as NYHA Class I, II, or III — confirm with trial site if unsure which class applies)
  • People whose heart pumping function, measured by an ultrasound of the heart, falls within a specific range (confirm with trial site for exact values)
  • People who have had a heart device fitted (either an ICD or CRT-D, which are devices that monitor and correct dangerous heart rhythms) for more than 3 months before joining the trial

Who may not be able to join:

  • People with any long-term medical condition that the trial doctors believe could put them at risk or make it difficult to take part safely
  • People who were admitted to hospital in the 3 months before signing up for any of the following: heart failure, serious heart rhythm problems that needed external electric shock treatment, or repeated shocks from their implanted heart device
  • People who have needed, or are expected to need, a mechanical heart pump device or a heart transplant due to severe heart failure
  • People who currently need, or are expected to need, heart-strengthening medication given continuously through a drip (IV)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
Phase 2: approximately ~30% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 2
Sponsor
Nuevocor Pte. Ltd.
Registry
ClinicalTrials.gov
Start date
16 June 2026
Est. completion
1 March 2030

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Safety: Frequency, severity, and relatedness of treatment-emergent adverse events (TEAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov